# Effect of G17DT in Patients With Stage II/III Colorectal Cancer

> **NCT02518373** · PHASE2 · COMPLETED · sponsor: **Cancer Advances Inc.** · enrollment: 22 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** G17DT
- **DRUG:** Omeprazole

## Key facts

- **NCT ID:** NCT02518373
- **Lead sponsor:** Cancer Advances Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** 2001-02
- **Final completion:** 2001-02
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2015-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02518373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02518373, "Effect of G17DT in Patients With Stage II/III Colorectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02518373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*